论文部分内容阅读
乳腺癌是妇女最常见的恶性肿瘤,是一种异质性疾病,根据其细胞表面受体类型的不同,需采用不同的治疗策略,常见的受体有孕激素受体(PR)、雌激素受体(ER)和人表皮生长因子受体-2(HER-2)~([1])。其中HER-2是具有酪氨酸激酶活性的穿膜受体,参与调控细胞增殖、存活及分化~([2])。曲妥珠单抗是一种应用于靶向治疗HER-2阳性乳腺癌的单克隆抗体,可与HER-2的胞外结构域结合,并选择性阻断HER-
Breast cancer is the most common malignant tumor in women and is a heterogeneous disease. According to the different types of cell surface receptors, different treatment strategies should be adopted. Common receptors are progesterone receptor (PR), estrogen Receptor (ER) and human epidermal growth factor receptor-2 (HER-2) ~ ([1]). Among them, HER-2 is a transmembrane receptor with tyrosine kinase activity and is involved in the regulation of cell proliferation, survival and differentiation ~ ([2]). Trastuzumab, a monoclonal antibody that is used in targeted therapy of HER-2 positive breast cancer, binds to the extracellular domain of HER-2 and selectively blocks HER-